Cart
Free Shipping in Australia
Proud to be B-Corp

Therapeutic Targets of the TNF Superfamily Iqbal S. Grewal

Therapeutic Targets of the TNF Superfamily By Iqbal S. Grewal

Therapeutic Targets of the TNF Superfamily by Iqbal S. Grewal


$320.89
Condition - New
Only 2 left

Summary

What has emerged over the years is that most TNF ligands bind to one distinct receptor and some of the TNF ligands are able to bind to multiple TNF receptors, explaining to some extent the apparent disparity in the number of TNF receptors and ligands.

Therapeutic Targets of the TNF Superfamily Summary

Therapeutic Targets of the TNF Superfamily by Iqbal S. Grewal

Tumor necrosis factor (TNF) superfamily is a rapidly growing family of cytokines that interacts with a corresponding superfamily of receptors. Liga- receptor interactions of this superfamily are involved in numerous biological processes ranging from hematopoiesis to pleiotropic cellular responses, including activation, proliferation, differentiation, and apoptosis. The particular response depends on the receptor, the cell type, and the concurrent signals received by the cell. Worldwide interest in the TNF field surged dramatically early in 1984 with the cloning and defining of the profound cellular effects of the first member of this family, TNF . Subsequently, the major influence of TNF on the development and functioning of the immune system was established. Today, over 20 human TNF ligands and their more than 30 corresponding receptors have been identified. Few receptors still remain orphans. What has emerged over the years is that most TNF ligands bind to one distinct receptor and some of the TNF ligands are able to bind to multiple TNF receptors, explaining to some extent the apparent disparity in the number of TNF receptors and ligands. Yet, in spite of some redundancy in TNF ligand/receptor interactions, it is clear that in vivo spatial, temporal, and indeed cell- and tissue-specific expression of both ligands and their receptors are important factors in determining the precise nature of cellular, physiological and pathological processes they control. TNF superfamily has been the most highly investigated area of basic medical research for over two decades.

About Iqbal S. Grewal

Iqbal S. Grewal, PhD is well-known in the field of T cell co-stimulation and autoimmunity and has extensively investigated several members of the TNF superfamily and molecules important for lymphocyte co-stimulation. His research has focused on the basic molecular and cellular processes to determine the biological roles of these molecules in normal physiology and immunity and their potential utility as agents or targets for the treatment of autoimmune diseases and cancers. His experience in discovering and developing innovative protein-based biotherapeutics in many disease areas has translated some of his findings into key drug candidates for the treatment of autoimmune disease and cancers.

Dr Grewal currently holds the position of Vice President of Preclinical Therapeutics at Seattle Genetics in Bothell, Washington. He is responsible for preclinical translational research functions in support of the development of monoclonal antibodies and antibody-drug conjugates as therapeutics in the areas of autoimmunity and oncology. Before joining Seattle Genetics, Dr Grewal performed drug discovery research and preclinical development at Genentech in South San Francisco, California where he identified and validated several novel molecules as therapeutic candidates in oncology and autoimmune disease. Prior to Genentech, Dr Grewal worked at Yale University School of Medicine. Before that, he held various research positions at the University of California, Los Angeles (UCLA). Dr Grewal has presented his work at both national and international meetings, as well as published over 100 scientific publications, 75 abstracts, 60 patent applications. He is a fellow of the Royal College of Pathologists, London and member of several distinguished societies. Dr Grewal holds a PhD in Immunology from UCLA and completed his post-doctoral fellowship at Howard Hughes Medical Institute at Yale University School of Medicine.

Table of Contents

1. Overview of TNF Superfamily: A Chest Full of Potential Therapeutic Targets Iqbal S. Grewal Abstract Introduction Therapeutic Potential of TNF Superfamily for Anticancer Treatment Therapeutic Potential of TNF Superfamily for Autoimmune and Inflammatory Disease Challenges for Targeting TNF Superfamily Members Summary and Conclusions 2. Therapeutic Interventions Targeting CD40L (CD154) and CD40: The Opportunities and Challenges Che-Leung Law and Iqbal S. Grewal Abstract Introduction CD40L Expression in Autoimmune and Inflammatory Conditions CD40-Mediated Inflammatory Reaction Genetic Evidence for the Contribution of CD40-CD40L Interaction in Experimental Autoimmune and Inflammatory Diseases Therapeutic Targeting of CD40L: Proof of Concept Preclinical Animal Models of Autoimmunity and Inflammation Clinical Experience with Anti-CD40L Mechanism(s) of Action of Anti-CD40L mAbs: Toxicity versus Efficacy Potential Alternative Therapeutic Approaches Targeting CD40L CD40 Signaling in Transformed Cells CD40 and Cancer Immune Surveillance Characteristics of Anti-CD40 Antibodies Clinical Experience in Therapeutic Targeting of CD40 Considerations for Therapeutics Targeting CD40 Conclusions 3. Targeting TNF for Treatment of Cancer and Autoimmunity Gautam Sethi, Bokyung Sung, Ajaikumar B. Kunnumakkara and Bharat B. Aggarwal Abstract Discovery of TNF Signaling Mechanism(s) by TNF-a Role of TNF-a in Cancer Role of TNF-a in the Immune System Role of TNF-a in Autoimmune Diseases TNF Inhibitors Natural Products as Inhibitors of TNF Conclusion 4. Targeting of BAFF and APRIL for Autoimmunity and Oncology Maureen C. Ryan and Iqbal S. Grewal Abstract Introduction The BAFF and APRIL Receptor/Ligand System BAFF and APRIL Regulate Immune Functions BAFF and APRIL in Autoimmunity APRIL and BAFF in Cancer Parallels between Autoimmunity and Cancer New Therapeutics for Autoimmunity and Cancer Future Applications, New Research, Anticipated Developments 5. The Role of FasL and Fas in Health and Disease Martin Ehrenschwender and Harald Wajant Abstract The FasL-Fas System The FasL-Fas System in Health and Disease Therapeutic Concepts Targeting the FasL-Fas System 6. OX40 (CD134) and OX40L Michael J. Gough and Andrew D. Weinberg Abstract Expression of OX40 and OX40L Biologic Function of OX40-OX40L Interactions Expression and Role of OX40 and OX40L in Disease Intervention in OX40-OX40L Interaction for Therapy Conclusion 7. Targeting CD70 for Human Therapeutic Use Tamar Boursalian, Julie McEarchern, Che-Leung Law and Iqbal S. Grewal Abstract Introduction CD70 Expression and Biology CD70 in Autoimmunity CD70 in Oncology Conclusions and Future Directions 8. 4-1BB as a Therapeutic Target for Human Disease Seung-Woo Lee and Michael Croft Abstract Introduction to Basic Research Expression of 4-1BB and 4-1BBL Therapeutic Effects of Targeting 4-1BB or 4-1BBL Possible Mechanisms of Action of 4-1BB Agonistic Antibodies Concluding Remarks 9. RANK(L) as a Key Target for Controlling Bone Loss Andreas Leibbrandt and Josef M. Penninger Abstract Overview Basic Characteristics of the RANKL-RANK-OPG Axis Bone Remodeling and the RANKL-RANK-OPG Axis RANK(L) Signaling Pathways RANK(L) Signaling in the Immune System<

Additional information

NLS9781441927996
9781441927996
1441927999
Therapeutic Targets of the TNF Superfamily by Iqbal S. Grewal
New
Paperback
Springer-Verlag New York Inc.
2010-12-06
220
N/A
Book picture is for illustrative purposes only, actual binding, cover or edition may vary.
This is a new book - be the first to read this copy. With untouched pages and a perfect binding, your brand new copy is ready to be opened for the first time

Customer Reviews - Therapeutic Targets of the TNF Superfamily